BioStock: Xintela’s CEO on recent successes

Report this content

Recently, promising results from Xintela’s preclinical glioblastoma study were published in the reputable journal Cancers. In addition, the company has obtained an approved patent for the stem cell product XSTEM from the European Patent Office and a tissue establishment license from the Medical Products Agency. BioStock contacted Xintela’s CEO Evy Lundgren-Åkerlund to learn more about the recent positive news.

Read the full article at
This is a press release from BioStock - Connecting Innovation & Capital.


Documents & Links

Quick facts

BioStock: Xintela’s CEO on recent successes
Tweet this